KCA
Search
- Page Path
- HOME > Search
Original Articles
- Lung and Thoracic cancer
- Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
- Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang
- Cancer Res Treat. 2024;56(1):48-60. Published online June 27, 2023
- DOI: https://doi.org/10.4143/crt.2023.453
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).
Materials and Methods
Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results
In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion
Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population. -
Citations
Citations to this article as recorded by
- HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer
Mohammad Hassan Baig, Chang Joong Kim, Nale Sagar Dattatraya, Jo Yun Seong, Juhan Bok, Hyemi Kim, JiMin Park, Munkyung Choi, Sang‐Heon Kim, ByoungGon Moon, Jaejune Dong, Sangyoon Yi, Sungwook Ryu
Archiv der Pharmazie.2026;[Epub] CrossRef - Solid phase extraction and high-performance liquid chromatographic determination of lazertinib in human plasma
Yoshito Gando, Takeo Yasu
Drug Discoveries & Therapeutics.2025; 19(5): 346. CrossRef - First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis
Wei Du, Anlin Li, Bijing Xiao, Yunpeng Yang, Wenfeng Fang, Yan Huang, Shaodong Hong, Li Zhang
MedComm.2025;[Epub] CrossRef - First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis
Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun, Chengbo Han
Scientific Reports.2024;[Epub] CrossRef
- HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer
- 11,991 View
- 639 Download
- 6 Web of Science
- 4 Crossref
- Sarcoma
- Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression
- Heejung Chae, Jeong Eun Kim, Wanlim Kim, Jong-Seok Lee, Si Yeol Song, Min Hee Lee, Hye Won Chung, Kyung-Ja Cho, Joon Seon Song, Jin-Hee Ahn
- Cancer Res Treat. 2022;54(2):579-589. Published online July 6, 2021
- DOI: https://doi.org/10.4143/crt.2021.496
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
For liposarcoma (LPS), clinical course and proper treatment strategies have not been well-established. Recently, immune-checkpoint inhibitors have shown potential efficacy in LPS. We aimed to describe the clinical course of LPS and evaluate the clinical impact of programmed death-ligand 1 (PD-L1).
Materials and Methods
We reviewed all consecutive patients (n=332) who underwent curative-intent surgery for localized LPS at Asan Medical Center between 1989 and 2017. PD-L1 testing was performed in well-differentiated and dedifferentiated LPS.
Results
The median age was 56 years with males comprising 60.8%. Abdomen-pelvis (47.6%) and well-differentiated (37.7%) were the most frequent primary site and histologic subtype, respectively. During a median follow-up of 81.2 months, recurrence was observed in 135 (40.7%), and 86.7% (117/135) were loco-regional. Well-differentiated subtype (hazard ratio [HR], 0.38), abdomen-pelvis origin (HR, 2.43), tumor size larger than 5 cm (HR, 1.83), positive resection margin (HR, 2.58), and postoperative radiotherapy (HR, 0.36) were significantly related with recurrence-free survival as well as visceral involvement (HR, 1.84) and multifocality (HR, 3.79) in abdomen-pelvis LPS. PD-L1 was positive in 31.5% (23/73) and 51.3% (39/76) of well-differentiated and dedifferentiated LPS, respectively, but had no impact on survival outcomes.
Conclusion
Clinical course of LPS was heterogeneous according to histology and anatomic location. Clear resection margin was important to lower recurrence and postoperative radiotherapy might have additional benefit. A decent portion of well-differentiated and dedifferentiated LPS were positive for PD-L1, but its prognostic role was unclear. Further research is needed to determine clinical implications of PD-L1, especially for advanced-stage LPS with unmet needs for effective systemic treatment. -
Citations
Citations to this article as recorded by- Recurrent Intrathoracic Liposarcoma: A Case Report and a Comprehensive Literature Review of a Rare Clinical Entity
Vasileios Leivaditis , Manfred Dahm , Athanasios Papatriantafyllou, Hans-Georg Keul, Lydia Kohl, Hans-Joachim Schäfers
Cureus.2024;[Epub] CrossRef - Clinicopathological Features of Intrathoracic Liposarcoma—A Systematic Review with an Illustrative Case
Kajetan Kiełbowski, Nikola Ruszel, Seweryn Adam Skrzyniarz, Małgorzata Edyta Wojtyś, Rafał Becht, Konrad Ptaszyński, Darko Gajić, Janusz Wójcik
Journal of Clinical Medicine.2022; 11(24): 7353. CrossRef
- Recurrent Intrathoracic Liposarcoma: A Case Report and a Comprehensive Literature Review of a Rare Clinical Entity
- 8,556 View
- 123 Download
- 1 Web of Science
- 2 Crossref
- Lung cancer
- Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
- Sun Min Lim, Sang-We Kim, Byoung Chul Cho, Jin Hyung Kang, Myung-Ju Ahn, Dong-Wan Kim, Young-Chul Kim, Jin Soo Lee, Jong-Seok Lee, Sung Yong Lee, Keon Uk Park, Ho Jung An, Eun Kyung Cho, Tae Won Jang, Bong-Seog Kim, Joo-Hang Kim, Sung Sook Lee, Im-II Na, Seung Soo Yoo, Ki Hyeong Lee
- Cancer Res Treat. 2020;52(4):1112-1119. Published online May 15, 2020
- DOI: https://doi.org/10.4143/crt.2020.245
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.
Materials and Methods
Previously treated patients with advanced non-squamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected.
Results
Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data.
Conclusion
This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, including those with an older age. -
Citations
Citations to this article as recorded by- Advances in reprogramming of energy metabolism in tumor T cells
Liu Xuekai, Song Yan, Chu Jian, Song Yifei, Wu Xinyue, Zhang Wenyuan, Han Shuwen, Yang Xi
Frontiers in Immunology.2024;[Epub] CrossRef - Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Ning Wan, Yongbang Chen, Liqing Lu, Bing Wang, Liuliu He, Hongyi Liang, Fei Xie, Xiaoshun Jian, Bo Ji, Jianping Zhang, Hammoda Abu-Odah
European Journal of Cancer Care.2024; 2024: 1. CrossRef - Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer
Qiang Chen, Shuo Ying, Jianwen Qin, Li Zhang
Frontiers in Oncology.2024;[Epub] CrossRef - Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index
Ana Ortega-Franco, Clare Hodgson, Haseem Raja, Mathew Carter, Colin Lindsay, Sarah Hughes, Laura Cove-Smith, Paul Taylor, Yvonne Summers, Fiona Blackhall, Raffaele Califano
Targeted Oncology.2022; 17(4): 453. CrossRef - Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
Handai Xia, Wengang Zhang, Yuqing Zhang, Xiaoling Shang, Yanguo Liu, Xiuwen Wang
Frontiers in Oncology.2022;[Epub] CrossRef - Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
Donghui Wang, Cen Chen, Yanli Gu, Wanjun Lu, Ping Zhan, Hongbing Liu, Tangfeng Lv, Yong Song, Fang Zhang
Frontiers in Oncology.2021;[Epub] CrossRef - Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer
Min Jung Geum, Chungsoo Kim, Ji Eun Kang, Jae Hee Choi, Jae Song Kim, Eun Sun Son, Sun Min Lim, Sandy Jeong Rhie
Pharmaceuticals.2021; 14(5): 445. CrossRef - Nivolumab
Reactions Weekly.2021; 1855(1): 269. CrossRef - Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
Zhe Zhao, Xinfeng Wang, Jinghan Qu, Wei Zuo, Yan Tang, Huijuan Zhu, Xiaoguang Chen
Frontiers in Oncology.2021;[Epub] CrossRef
- Advances in reprogramming of energy metabolism in tumor T cells
- 13,708 View
- 322 Download
- 16 Web of Science
- 9 Crossref
- Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
- Junghoon Shin, Jin-Haeng Chung, Se Hyun Kim, Kyu Sang Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jeong-Ok Lee, Jin-Won Kim, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee
- Cancer Res Treat. 2019;51(3):1086-1097. Published online November 5, 2018
- DOI: https://doi.org/10.4143/crt.2018.537
-
Abstract
PDFPubReaderePub
- Purpose
Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications.
Materials and Methods
We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival.
Results
The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1‒negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival.
Conclusion
Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome. -
Citations
Citations to this article as recorded by- Association of PD‐L1 Expression With Tertiary Lymphoid Structures and Prognosis in Oral Cancer
Emi Saitou, Mai Seki, Takaaki Sano, Masaru Ogawa, Satoshi Yokoo, Tetsunari Oyama
Head & Neck.2026; 48(1): 26. CrossRef - Programmed death-ligand 1 upregulation is associated with poor prognosis in patients with epithelial ovarian cancer
Chia-Hao Liu, Wei-Ting Chao, Szu-Ting Yang, Chen-Hao Lin, Kuo-Chang Wen, Peng-Hui Wang
Journal of the Chinese Medical Association.2026; 89(1): 25. CrossRef - Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project
Martina Haberecker, Jan H. Rüschoff, Charitini Andriakopoulou, Steven G. Gray, Kristiaan Nackaerts, Marc De Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Luca Ampollini, Joachim G. Aerts, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fate
JCO Precision Oncology.2025;[Epub] CrossRef - Selenium-containing compounds, selenium nanoparticles and selenoproteins in the prevention and treatment of lung cancer
Elena G. Varlamova
Journal of Trace Elements in Medicine and Biology.2025; 88: 127620. CrossRef - Recent advances in PD-L1 siRNA nanocarriers for cancer therapy
Sristi, Garima Gupta, Mohammed A.S. Abourehab, Amirhossein Sahebkar, Prashant Kesharwani
International Journal of Biological Macromolecules.2025; 311: 143994. CrossRef - Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy
Xinmin Wang, Jing Jing
MedComm.2025;[Epub] CrossRef - Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?
Shengyu Zhu, Jianjiang Liu, Xialin Chen, Sheng Jin
Medicine.2025; 104(36): e44383. CrossRef - Advances in cancer immunotherapy and future directions in personalized medicine
Yixuan Wang
Open Life Sciences.2025;[Epub] CrossRef - Clinical application and drug resistance mechanism of gemcitabine
Xuanrui Zhang, Bing Qi, Jing Chen
Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef - Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
H. H. Wang, E. N. Steffens, G. Kats-Ugurlu, B. van Etten, J. G. M. Burgerhof, G. A. P. Hospers, J. T. M. Plukker
Annals of Surgical Oncology.2024; 31(1): 433. CrossRef - Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiar
Frontiers in Oncology.2024;[Epub] CrossRef - First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Tanja D de Gruijl, Teodora Radonic, Suresh Senan, C Willemien Menke-van der Houven van O
Journal for ImmunoTherapy of Cancer.2024; 12(2): e007659. CrossRef - Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Pauline Hulo, Sophie Deshayes, Judith Fresquet, Anne-Laure Chéné, Stéphanie Blandin, Nicolas Boisgerault, Jean-François Fonteneau, Lucas Treps, Marc G Denis, Jaafar Bennouna, Delphine Fradin, Elvire Pons-Tostivint, Christophe Blanquart
Respiratory Research.2024;[Epub] CrossRef - Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
Breast Cancer Research and Treatment.2024; 207(2): 301. CrossRef - Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Tomohito Okano, Taro Yasuma, Esteban C. Gabazza, Hidenori Ibata, Tetsu Kobayashi
Diagnostics.2024; 14(19): 2159. CrossRef - Cryoablation plus chemotherapy regimen enhance anti-tumor immune response in a mouse model of Lewis lung cancer
Hua Duan, Li Yang, Xueni Fang, Shaohua Yan, Yang Cao, Bingli Qiao, Tian Zhou, Kaiwen Hu
International Journal of Hyperthermia.2024;[Epub] CrossRef - Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade—Reply
Biagio Ricciuti, Xinan Wang, Mark M. Awad
JAMA Oncology.2023; 9(4): 570. CrossRef - Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study
Kazuma Sakura, Masao Sasai, Soichiro Funaki, Yasushi Shintani, Meinoshin Okumura, Yasufumi Kaneda
Cancers.2023; 15(3): 929. CrossRef - Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo
Journal for ImmunoTherapy of Cancer.2023; 11(2): e006464. CrossRef - Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D. König, S. Savic Prince, S. Hayoz, P. Zens, S. Berezowska, W. Jochum, E. Stauffer, V. Braunersreuther, B. Trachsel, S. Thierstein, M. Mark, S. Schmid, A. Curioni-Fontecedro, A. Addeo, I. Opitz, M. Guckenberger, M. Früh, D.C. Betticher, H.-B. Ris, R. Stu
ESMO Open.2023; 8(4): 101595. CrossRef - Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells
Chen Fu, Zongcai Liu, Taixue An, Haixia Li, Xiumei Hu, Xin Li, Xinyao Liu, Danjuan Wu, Ruyi Zhang, Kui Li, Yurong Qiu, Haifang Wang
Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(10): 130439. CrossRef - Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1
Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura, Satoshi Hirano, Sukeyuki Nakamura
Journal of Thoracic Oncology.2023; 18(9): e93. CrossRef - Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Yu Zhao, Zhe Wang, Xiuhuan Shi, Ting Liu, Wenwen Yu, Xiubao Ren, Hua Zhao
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef - The Role of Regulatory T Cells in Cancer Treatment Resistance
Anna Dąbrowska, Magdalena Grubba, Amar Balihodzic, Olga Szot, Bartosz Kamil Sobocki, Adrian Perdyan
International Journal of Molecular Sciences.2023; 24(18): 14114. CrossRef - Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti‐PD‐L1 Therapy
Yucheng Xiang, Liqiang Chen, Chendong Liu, Xiaoli Yi, Lian Li, Yuan Huang
Small.2022;[Epub] CrossRef - FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
Weiqiang Jing, Ganyu Wang, Zhiwei Cui, Gaozhong Xiong, Xin Jiang, Yue Li, Wushan Li, Bo Han, Shouzhen Chen, Benkang Shi
Cancer Research.2022; 82(1): 114. CrossRef - The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Daniel R. Principe, Suneel D. Kamath, Murray Korc, Hidayatullah G. Munshi
Pharmacology & Therapeutics.2022; 236: 108111. CrossRef - Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
S. Park, J.-M. Sun, Y.-L. Choi, D. Oh, H.K. Kim, T. Lee, S.A. Chi, S.-H. Lee, Y.S. Choi, S.-H. Jung, M.-J. Ahn, Y.C. Ahn, K. Park, Y.M. Shim
ESMO Open.2022; 7(1): 100385. CrossRef - Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. La
Biomarker Research.2022;[Epub] CrossRef - Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
Hélène Kaplon
Frontiers in Oncology.2022;[Epub] CrossRef - Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
Salman Hussain, Jitka Klugarova, Miloslav Klugar
Lung Cancer.2022; 170: 11. CrossRef - Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression
Kaiyue Ding, Minhan Yi, Hui Liang, Zhongkui Li, Yuan Zhang
Expert Review of Clinical Immunology.2022; 18(7): 759. CrossRef - Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1
Tsung-Wei Chen, Wei-Ze Hung, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, Ji-An Liang, Chih-Yang Huang, Pei-Chen Yang, Kevin Chih-Yang Huang, K.S. Clifford Chao
Cancer Letters.2022; 543: 215795. CrossRef - SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
Seung Ho Baek, Jee Hung Kim, Soong June Bae, Jung Hwan Ji, Yangkyu Lee, Joon Jeong, Yoon Jin Cha, Sung Gwe Ahn
Cancers.2022; 14(13): 3042. CrossRef - Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona
Frontiers in Oncology.2022;[Epub] CrossRef - Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy?
D. I. Yudin, K. K. Laktionov
Medical alphabet.2022; (13): 18. CrossRef - The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
Philipp Zens, Corina Bello, Amina Scherz, Michael von Gunten, Adrian Ochsenbein, Ralph A. Schmid, Sabina Berezowska
Modern Pathology.2022; 35(12): 1848. CrossRef - MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
Roberto Cuttano, Miriam Kuku Afanga, Fabrizio Bianchi
Cancers.2022; 14(23): 5731. CrossRef - miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasqui
Journal of Hematology & Oncology.2022;[Epub] CrossRef - PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
Tahlia Scheinberg, Anna Lomax, Martin Tattersall, David Thomas, Geoff McCowage, Michael Sullivan, Rooshdiya Karim, Peter P. Luk, Annabelle Mahar, Fiona Bonar, Vivek A. Bhadri
Cancer Reports.2021;[Epub] CrossRef - PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?
Aoran Dong, Yiming Zhao, Zhihua Li, Hai Hu
The Journal of Gene Medicine.2021;[Epub] CrossRef - Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma
Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Mariko Aoyama, Naoya Kawakita, Yota Yamamoto, Furukita Yoshihito, Hiromitsu Takizawa, Akira Tangoku
General Thoracic and Cardiovascular Surgery.2021; 69(3): 525. CrossRef - Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer
Marina C Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang, Cathy O'Brien, Phillip A Denn
Future Oncology.2021; 17(10): 1165. CrossRef - Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
S. Sugawara, J.-S. Lee, J.-H. Kang, H.R. Kim, N. Inui, T. Hida, K.H. Lee, T. Yoshida, H. Tanaka, C.-T. Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C.-J. Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
Annals of Oncology.2021; 32(9): 1137. CrossRef - Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
The Korean Journal of Internal Medicine.2021; 36(4): 975. CrossRef - Methylseleninic acid overcomes programmed death‐ligand 1‐mediated resistance of prostate cancer and lung cancer
Wenli Hu, Yurong Ma, Chong Zhao, Shutao Yin, Hongbo Hu
Molecular Carcinogenesis.2021; 60(11): 746. CrossRef - Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy
Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora, Maria Mulet, Maria Soledad Garcia-Cuerva, Ana Palomino, Georgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal
Biomedicines.2021; 9(9): 1125. CrossRef - Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions
Daun Jung, Young Seok Baek, In Jee Lee, Ki Yeon Kim, Heejoo Jang, Sohyun Hwang, Jieun Jung, Yong-wha Moon, Kyung-Soon Park, Yong-Soo Choi, Hee Jung An
Journal of Experimental & Clinical Cancer Research.2021;[Epub] CrossRef - Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
Torben Steiniche, Sun Young Rha, Hyun Cheol Chung, Jeanette Baehr Georgsen, Morten Ladekarl, Marianne Nordsmark, Marie Louise Jespersen, Hyo Song Kim, Hyunki Kim, Carly Fein, Laura H. Tang, Ting Wu, Matthew J. Marton, Senaka Peter, David P. Kelsen, Geoffr
Cancer Medicine.2021; 10(23): 8365. CrossRef - A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody
Eun Ji Lee, Gun-Young Jang, Sung Eun Lee, Ji won Lee, Hee Dong Han, Yeong-Min Park, Tae Heung Kang
Immunology Letters.2021; 240: 137. CrossRef - Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
Lei Tu, Renguo Guan, Hanting Yang, Yu Zhou, Weifeng Hong, Liheng Ma, Guangzhe Zhao, Min Yu
International Journal of Cancer.2020; 147(2): 423. CrossRef - Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu
World Journal of Surgical Oncology.2020;[Epub] CrossRef - Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
Kathrin Gennen, Lukas Käsmann, Julian Taugner, Chukwuka Eze, Monika Karin, Olarn Roengvoraphoj, Jens Neumann, Amanda Tufman, Michael Orth, Simone Reu, Claus Belka, Farkhad Manapov
Radiation Oncology.2020;[Epub] CrossRef - PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer
Jaanika Narits, Hannes Tamm, Jana Jaal
Clinical and Translational Radiation Oncology.2020; 22: 83. CrossRef - Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Yun Liang, Minghua Yu, Caiyun Zhou, Xiaojun Zhu
Diagnostic Pathology.2020;[Epub] CrossRef - Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
Rui Jin, Jing Zhao, Lexin Xia, Qin Li, Wen Li, Ling Peng, Yang Xia
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef - Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
Dovile Zilenaite, Allan Rasmusson, Renaldas Augulis, Justinas Besusparis, Aida Laurinaviciene, Benoit Plancoulaine, Valerijus Ostapenko, Arvydas Laurinavicius
Frontiers in Oncology.2020;[Epub] CrossRef - Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer
Nature Reviews Clinical Oncology.2020; 17(12): 725. CrossRef - Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression
Malene Støchkel Frank, Uffe Bødtger, Asbjørn Høegholm, Inger Merete Stamp, Julie Gehl
Lung Cancer.2020; 149: 23. CrossRef - The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino
Cancers.2020; 12(11): 3129. CrossRef - The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment
Avital Vorontsova, Tal Kan, Ziv Raviv, Yuval Shaked
Journal of Clinical Medicine.2020; 9(12): 3912. CrossRef - Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non–small Cell Lung Cancer Recurrence
Max Lacour, Stefanie Hiltbrunner, Seok-Yun Lee, Alex Soltermann, Elisabeth Jane Rushing, Davide Soldini, Walter Weder, Alessandra Curioni-Fontecedro
Clinical Lung Cancer.2019; 20(5): 391. CrossRef - PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2019; 53(4): 199. CrossRef
- Association of PD‐L1 Expression With Tertiary Lymphoid Structures and Prognosis in Oral Cancer
- 14,704 View
- 495 Download
- 69 Web of Science
- 63 Crossref
- Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
- Cancer Res Treat. 2018;50(3):835-842. Published online August 29, 2017
- DOI: https://doi.org/10.4143/crt.2017.303
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Poziotinib, a pan-human epidermal growth factor receptor 2 (HER) tyrosine kinase inhibitor, has shown potent activity againstwild type of epidermal growth factorreceptor(EGFR) family kinases including EGFR, HER2, and HER4 and EGFR-mutant cells in vitro. Two phase I studies were conducted to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity against advanced solid tumors.
Materials and Methods
Standard 3+3 dose escalation scheme using two different dosing schedules were studied: once daily, 14-day on, and 7-day off (intermittent schedule); and once daily continuous dosing with food effect. Additional patients were enrolled in an expansion cohort.
Results
A total of 75 patients were enrolled in the two studies. The most common drug-related treatment-emergent adverse eventswere diarrhea,rash, stomatitis, pruritus, and anorexia. Doselimiting toxicities were grade 3 diarrhea in the intermittent schedule and grade 3 anorexia and diarrhea in the continuous dosing schedule. The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule. Eight (16%) and 24 (47%) of 51 evaluable patients in the intermittent schedule achieved partial response (PR) and stable disease (SD), respectively. Four (21%) and six (32%) of 19 evaluable patients in continuous dosing schedule achieved PR and SD, respectively. Patients with PR (n=7) or SD ≥ 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer).
Conclusion
Poziotinib was safe and well tolerated in patients with advanced solid tumors. It showed an encouraging activity against EGFR-mutant and HER2-amplified cancers. -
Citations
Citations to this article as recorded by- What for patients with NRG1 fusions? Looking into Pandora's box
Domenico Trombetta, Antonio Rossi, Marco Donatello Delcuratolo, Francesco Pio Guerra, Federico Pio Fabrizio, Angelo Sparaneo, Francesco Delli Muti, Antonella Centonza, Paola Parente, Lucia Anna Muscarella
Critical Reviews in Oncology/Hematology.2026; 222: 105285. CrossRef - Clinical Efficacy of HER2-targeted Monotherapy in ERBB2-mutant Non–Small-Cell Lung Cancer: A Systematic Review and Single-arm Meta-Analysis
Fumihiro Kashizaki, Ryusuke Orii, Shohei Watanabe, Kentaro Yumoto
Clinical Lung Cancer.2026; 27(5): 55. CrossRef - The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, Adrian Sacher, Paul Wheatley-Price, Stephanie Snow, Ming-Sound Tsao, Natasha B. Leighl, Ilidio Martins, Parneet Cheema, Geoffrey Liu, Quincy S. C. Chu
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef - Cellular polarity pilots breast cancer progression and immunosuppression
Jie Huang, Shufeng Luo, Juan Shen, Maya Lee, Rachel Chen, Shenglin Ma, Lun-Quan Sun, Jian Jian Li
Oncogene.2025; 44(12): 783. CrossRef - The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
Danyyl Ippolitov, Yi-Han Lin, Jeremy Spence, Aleksandra Glogowska, Thatchawan Thanasupawat, Jason Beiko, Marc R. Del Bigio, Xin Xu, Amy Q. Wang, Darian Williams, Raul Calvo, Abhijeet Kapoor, Juan J. Marugan, Mark J. Henderson, Thomas Klonisch, Sabine Homb
Cancer Research.2025; 85(8): 1514. CrossRef - EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study
Sen Yang, Yang Liu, Jiuzhou Zhao, Zhen He, Haiyang Chen, Shuxiang Ma, Yingxi Wu, Yufeng Wu, Lili Wang, Cuicui Zhang, Qiming Wang
BMC Cancer.2025;[Epub] CrossRef - Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, Masato Chiba, Masaki Shimoji, Masaoki Ito, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani, Tetsuya Mitsudomi
Journal of Thoracic Oncology.2024; 19(1): 71. CrossRef - Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu-Yun Leu, Gajanan Bhat, Adam Brufsky
Breast Cancer Research and Treatment.2024; 205(1): 29. CrossRef - HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do-Youn Oh
Nature Reviews Clinical Oncology.2024; 21(9): 675. CrossRef - Emerging Targeted Therapies for HER2-Positive Breast Cancer
María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci
Cancers.2023; 15(7): 1987. CrossRef - Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
Shuanghu Wang, Mengming Xia, Yu Wang, Zebei Lu, Peiwu Geng, Dapeng Dai, Yunfang Zhou, Qingjun Wu
Thoracic Cancer.2023; 14(14): 1276. CrossRef - Neratinib for HER2-positive breast cancer with an overlooked option
Liting Guo, Weiwei Shao, Chenfei Zhou, Hui Yang, Liu Yang, Qu Cai, Junqing Wang, Yan Shi, Lei Huang, Jun Zhang
Molecular Medicine.2023;[Epub] CrossRef - Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Kenichi Suda, Kazuko Sakai, Hidenori Sato, Tetsuya Mitsudomi
JTO Clinical and Research Reports.2023; 4(9): 100554. CrossRef - Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker
Cancer Research.2023; 83(18): 3145. CrossRef - In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes
Salman Alamery, Anfal AlAjmi, Tanveer A. Wani, Seema Zargar
Medicina.2023; 59(11): 1923. CrossRef - Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
María José Bravo, Antonio Manuel Burgos-Molina, Marilina García-Aranda, Maximino Redondo, Teresa Téllez
Cancers.2023; 15(23): 5499. CrossRef - Novel HER-2 Targeted Therapies in Breast Cancer
Catarina Lopes Fernandes, Diogo J. Silva, Alexandra Mesquita
Cancers.2023; 16(1): 87. CrossRef - Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer
Jiyun Lee, Yeon Hee Park
Future Oncology.2022; 18(1): 7. CrossRef - Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski
Journal of Clinical Oncology.2022; 40(7): 710. CrossRef - HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
Xin Yu, Xianxiu Ji, Chunxia Su
Frontiers in Oncology.2022;[Epub] CrossRef - Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
Cancer Cell.2022; 40(7): 754. CrossRef - Tailoring antiHer2 treatment strategies in breast cancer and beyond
Palma Fedele, Valeria Sanna, Anna Natalizia Santoro, Maria Laura Iaia, Alessandro Fancellu
Current Problems in Cancer.2022; 46(5): 100892. CrossRef - HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
Biomarker Research.2022;[Epub] CrossRef - Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman
Journal of Personalized Medicine.2022; 12(10): 1651. CrossRef - An ultra-performance LC–MS/MS method for determination of JRF103 in human plasma: application in first in-patient study
Ying Jin, Xiangjie Di, Lisha Fu, Mengyu Zhang, Neng Qiu, Runhan Liu, Fangqun Li, Xiaohui Qi, Xiaoxu Wang, Yongsheng Wang, Zhenlei Wang
Bioanalysis.2022; 14(17): 1165. CrossRef - Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
Critical Reviews in Oncology/Hematology.2021; 160: 103299. CrossRef -
Effects of dacomitinib on the pharmacokinetics of poziotinib
in vivo
and
in vitro
Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Dapeng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou
Pharmaceutical Biology.2021; 59(1): 455. CrossRef - Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
Lara Ulrich, Alicia FC Okines
Breast Cancer: Targets and Therapy.2021; Volume 13: 361. CrossRef - Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef - The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
Barbara Melosky, Paul Wheatley-Price, Rosalyn A. Juergens, Adrian Sacher, Natasha B. Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B. Card, Quincy Chu
Lung Cancer.2021; 160: 136. CrossRef - Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
Chia-Jung Li, Yen-Dun Tony Tzeng, Yi-Han Chiu, Hung-Yu Lin, Ming-Feng Hou, Pei-Yi Chu
Cancers.2021; 13(12): 2978. CrossRef - Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
Debasis Das, Jingbing Wang, Jian Hong
ChemMedChem.2021; 16(16): 2459. CrossRef - Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors
Seyed-Omar Zaraei, Rawan M. Sbenati, Nour N. Alach, Hanan S. Anbar, Randa El-Gamal, Hamadeh Tarazi, Mahmoud K. Shehata, Mohammed S. Abdel-Maksoud, Chang-Hyun Oh, Mohammed I. El-Gamal
European Journal of Medicinal Chemistry.2021; 224: 113674. CrossRef - Breast Cancer Treatments: Updates and New Challenges
Anna Burguin, Caroline Diorio, Francine Durocher
Journal of Personalized Medicine.2021; 11(8): 808. CrossRef - Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
M. Riudavets, I. Sullivan, P. Abdayem, D. Planchard
ESMO Open.2021; 6(5): 100260. CrossRef - A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
Cancer Medicine.2021; 10(20): 7012. CrossRef - In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuro Uchida, Tetsuya Mitsudomi
Lung Cancer.2021; 162: 79. CrossRef - HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
Ioannis A. Vathiotis, Andriani Charpidou, Niki Gavrielatou, Konstantinos N. Syrigos
Pharmaceuticals.2021; 14(12): 1300. CrossRef - Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang
Journal of Thoracic Oncology.2020; 15(6): 962. CrossRef - Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian Xu
Pharmacology & Therapeutics.2020; 206: 107438. CrossRef - Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
Critical Reviews in Oncology/Hematology.2020; 148: 102906. CrossRef - Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang, Xiaoyan Ma, Minghui Wang, Wenjing Wang, Songhui Zhao, Kai Wang, Song Gao, Li Zhang
The Oncologist.2020; 25(3): e545. CrossRef - Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel
Clinical Lung Cancer.2020; 21(5): 428. CrossRef - HER2-positive advanced breast cancer treatment in 2020
Marcelle G. Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja
Cancer Treatment Reviews.2020; 88: 102033. CrossRef - New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
Essia Mezni, Cécile Vicier, Mathilde Guerin, Renaud Sabatier, François Bertucci, Anthony Gonçalves
Cancers.2020; 12(6): 1573. CrossRef - HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang
Frontiers in Oncology.2020;[Epub] CrossRef - Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
Breast Cancer Research and Treatment.2020; 184(3): 743. CrossRef - EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Jordi Remon, Lizza E.L. Hendriks, Andres F. Cardona, Benjamin Besse
Cancer Treatment Reviews.2020; 90: 102105. CrossRef - Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni
Critical Reviews in Oncology/Hematology.2020; 156: 103119. CrossRef - Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
Xue Yang, Dapeng Wu, Shengli Yuan
Technology in Cancer Research & Treatment.2020;[Epub] CrossRef - Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
Cancers.2020; 12(11): 3249. CrossRef - Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo
Gastrointestinal Disorders.2020; 3(1): 1. CrossRef - Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
Apurva Pandey, Adam M. Brufsky
Clinical Breast Cancer.2019; 19(1): e7. CrossRef - Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
Debasis Das, Jian Hong
European Journal of Medicinal Chemistry.2019; 170: 55. CrossRef - Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Wei Jiang, Meiju Ji
Seminars in Cancer Biology.2019; 59: 3. CrossRef - A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
Tae-Yong Kim, Hye Sook Han, Keun-Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin-Soo Kim, Kyung-Hun Lee, Se Hoon Park, Eun-Kee Song, Soo-A Jung, NaMi Lee, Yeul Hong Kim, Jae Yong Cho, Yung-Jue Bang
Gastric Cancer.2019; 22(6): 1206. CrossRef - Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown
Cancers.2019; 11(6): 737. CrossRef - Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positi
Ji‐Yeon Kim, Eunjin Lee, Kyunghee Park, Hae Hyun Jung, Woong‐Yang Park, Kyung‐Hun Lee, Joohyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee Hyun Kim, Ki Hyeong Lee, Seock‐Ah Im, Yeon Hee Park
International Journal of Cancer.2019; 145(6): 1669. CrossRef - Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha
The Oncologist.2019; 24(12): e1303. CrossRef - Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Makoto Suzuki, Pasi A. Jänne, Tetsuya Mitsudomi
Lung Cancer.2018; 126: 72. CrossRef - A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial
Yeon Hee Park, Kyung‐Hun Lee, Joo Hyuk Sohn, Keun Seok Lee, Kyung Hae Jung, Jee‐Hyun Kim, Ki Hyeong Lee, Jin Seok Ahn, Tae‐Yong Kim, Gun Min Kim, In Hae Park, Sung‐Bae Kim, Se Hyun Kim, Hye Sook Han, Young‐Hyuck Im, Jin‐Hee Ahn, Jung‐Yong Kim, Jahoon Kang
International Journal of Cancer.2018; 143(12): 3240. CrossRef - EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Clinical Cancer Research.2018; 24(24): 6548. CrossRef
- What for patients with NRG1 fusions? Looking into Pandora's box
- 17,033 View
- 702 Download
- 65 Web of Science
- 62 Crossref
Case Report
- Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
- Junghoon Shin, Jeong-Ok Lee, Ji-Young Choe, Soo-Mee Bang, Jong-Seok Lee
- Cancer Res Treat. 2017;49(1):274-278. Published online June 10, 2016
- DOI: https://doi.org/10.4143/crt.2016.076
-
Abstract
PDFPubReaderePub
- Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin’s lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a detectable tumor. The effusion contains tumor cells universally infected with human herpesvirus 8 (HHV8), which is the critical factor differentiating PEL from HHV8-unrelated PEL-like lymphoma (PEL-LL). This report describes a 77-year-old male patient with pleural effusion and ascites, containing lymphoma cells expressing a B-cell phenotype, but without markers of HHV8 in immunocytochemical analysis. The patient was diagnosed with PEL-LL and treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. The patient is currently disease-free 15 months post-treatment. To the best of our knowledge, this is the first report on administration of R-CHOP in a PEL-LL patient in South Korea.
-
Citations
Citations to this article as recorded by- HIV-positive and HHV-8-negative primary effusion lymphoma complicated with coronary heart disease: a Case Report and literature review
Wei Zhang, Ying Zhang, Jing Yuan
Frontiers in Medicine.2025;[Epub] CrossRef - Fluid overload-associated large B-cell lymphoma: two case report and review of literature
Liudi Chang, Zhaobo Yang, Cuicui Yang, Yuxiao Wang, Dan Li, Hui Wang, Lanlan Zang, Yuanyuan Zhang
Frontiers in Oncology.2025;[Epub] CrossRef - Primary Effusion Lymphoma-like Lymphoma Mimicking Tuberculous Pleural Effusion: Three Case Reports and a Literature Review
Kenta Hayashino, Yusuke Meguri, Ryouya Yukawa, Aya Komura, Makoto Nakamura, Chikamasa Yoshida, Kazuhiko Yamamoto, Wakako Oda, Kenji Imajo
Internal Medicine.2023; 62(17): 2531. CrossRef - A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse
Xue Yan, Bin Chen, Hongxia Jing, Zhinan Yang, Ting Zhang, Yani Lin, Jinning Shi
Journal of Hematopathology.2023; 16(4): 235. CrossRef - Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV
Chih-Yi Liu, Bo-Jung Chen, Shih-Sung Chuang
Diagnostics.2022; 12(3): 713. CrossRef - Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8‐unrelated effusion large B‐cell lymphoma in vivo
Fumiya Ogasawara, Tomonori Higuchi, Tomohiro Nishimori, Yumiko Hashida, Kensuke Kojima, Masanori Daibata
Journal of Cellular and Molecular Medicine.2022; 26(22): 5580. CrossRef - Diagnostic significance of adenosine deaminase in pleural effusate for primary effusion lymphoma–like lymphoma
Soichiro Nakako, Mitsushige Nishimura, Yoshiro Murakami, Atsuko Mugitani
Clinical Case Reports.2020; 8(12): 3215. CrossRef - Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh
Cancer Research and Treatment.2019; 51(4): 1302. CrossRef - Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma
Tomomi Kubota, Yosuke Sasaki, Eisuke Shiozawa, Masafumi Takimoto, Tsunekazu Hishima, Ja-Mun Chong
American Journal of Surgical Pathology.2018; 42(12): 1607. CrossRef - A Case of Diffuse Large B-Cell Lymphoma Mimicking Primary Effusion Lymphoma-Like Lymphoma
Daisuke Usuda, Masahisa Arahata, Kento Takeshima, Ryusho Sangen, Akiteru Takamura, Yasuhiro Kawai, Yuji Kasamaki, Yoshitsugu Iinuma, Tsugiyasu Kanda
Case Reports in Oncology.2017; 10(3): 1013. CrossRef
- HIV-positive and HHV-8-negative primary effusion lymphoma complicated with coronary heart disease: a Case Report and literature review
- 11,437 View
- 200 Download
- 8 Web of Science
- 10 Crossref
Original Articles
- Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
- Do-Youn Oh, Tae-Min Kim, Sae-Won Han, Dong-Yeop Shin, Yun Gyoo Lee, Keun-Wook Lee, Jee Hyun Kim, Tae-You Kim, In-Jin Jang, Jong-Seok Lee, Yung-Jue Bang
- Cancer Res Treat. 2016;48(1):28-36. Published online February 23, 2015
- DOI: https://doi.org/10.4143/crt.2014.258
-
Abstract
PDFPubReaderePub
- Purpose
CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design. Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1.
Results
Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m2/day (n=3), 2 mg/m2/day (n=3), 3.3 mg/m2/day (n=3), 5 mg/m2/day (n=3), 7 mg/m2/day (n=3), 9 mg/m2/day (n=6), and 12 mg/m2/day (n=2). Mean age was 54 and 56.5% of patients were male. Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m2/day. The MTD was determined as 12 mg/m2/day. Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]). The pharmacokinetic study showed the dose-linearity of all dosing levels. Among 23 patients, six patients (26.1%) showed stable disease. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days). Conclusion This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor. MTD of CKD-516 was defined as 12 mg/m2/day on D1 and D8 every 3 weeks. -
Citations
Citations to this article as recorded by- Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics
Ahmed Kamal, Rahaman Shaik, Prasanna Anjaneyulu Yakkalaa
Expert Opinion on Investigational Drugs.2026; 35(4): 273. CrossRef - First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors
Xiao-Li Wei, Hao-Xiang Wu, Dan-Yun Ruan, Feng Wang, Li Xu, Yu-Hong Li, Yu-Xiang Ma, Zhi-Qiang Wang, Yun-Peng Yang, Liang-Wei Tang, Bao-Lin Chen, Zhi-Quan Yong, Rui-Hua Xu, Hong-Yun Zhao
Cell Reports Medicine.2025; 6(2): 101969. CrossRef - Natural‐Product‐Inspired Discovery of Trimethoxyphenyl‐1,2,4‐triazolosulfonamides as Potent Tubulin Polymerization Inhibitors
Vajja Krishna Rao, Anvesh Ashtam, Dulal Panda, Sankar K. Guchhait
ChemMedChem.2024;[Epub] CrossRef - Thiazole, Isatin and Phthalimide Derivatives Tested in vivo against
Cancer Models: A Literature Review of the Last Six Years
Aline Ferreira Pinto, Janine Siqueira Nunes, José Eduardo Severino Martins, Amanda Calazans Leal, Carla Cauanny Vieira Costa Silva, Anderson José Firmino Santos da Silva, Daiane Santiago da Cruz Olímpio, Elineide Tayse Noberto da Silva, Thiers Araújo Camp
Current Medicinal Chemistry.2024; 31(20): 2991. CrossRef - CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer
Soo Jin Kim, Kyunghyeon Lee, Jaewoo Park, Miso Park, U. Ji Kim, Se-mi Kim, Keun Ho Ryu, Keon Wook Kang
Toxicological Research.2023; 39(1): 61. CrossRef - Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer
Lance B. Augustin, Liming Milbauer, Sara E. Hastings, Arnold S. Leonard, Daniel A. Saltzman, Janet L. Schottel
Journal of Drug Targeting.2021; 29(4): 430. CrossRef - A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Hyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, Hyeong-Seok Lim, Joong Bae Ahn, Sang Joon Shin, Young Suk Park, Seung Tae Kim, Sae-Won Han, Tae-You Kim, Tae Won Kim
Investigational New Drugs.2021; 39(5): 1335. CrossRef - Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents
M. Shaheer Malik, Saleh A. Ahmed, Ismail I. Althagafi, Mohammed Azam Ansari, Ahmed Kamal
RSC Medicinal Chemistry.2020; 11(3): 327. CrossRef - Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus
Haiyang Yu, Na Shen, Yanli Bao, Li Chen, Zhaohui Tang
Biomaterials Science.2020; 8(1): 325. CrossRef - Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
Hark Kyun Kim, Jeong Won Kang, Young‐Whan Park, Jung Young Kim, Minchae Kim, Soo Jin Kim, Se‐mi Kim, Keun Ho Ryu, Seonghae Yoon, Yun Kim, Joo‐Youn Cho, Keun Seok Lee, Tak Yun, Kiwon Kim, Mi Hyang Kwak, Tae‐Sung Kim, Jinsoo Chung, Joong‐Won Park
Pharmacology Research & Perspectives.2020;[Epub] CrossRef - Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors
Mai F. Tolba
International Journal of Cancer.2020; 147(11): 2996. CrossRef - Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway
Jian Song, Qiu-Lei Gao, Bo-Wen Wu, Ting Zhu, Xin-Xin Cui, Cheng-Jun Jin, Shu-Yu Wang, Sheng-Hui Wang, Dong-Jun Fu, Hong-Min Liu, Sai-Yang Zhang, Yan-Bing Zhang, Yong-Chun Li
European Journal of Medicinal Chemistry.2020; 203: 112618. CrossRef - Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma
Min-Young Kim, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Yeon Sil Kim, Chan Kwon Jung, Jin-Hyoung Kang
BMC Cancer.2020;[Epub] CrossRef - Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors
Fang Yang, Cai-Ping He, Peng-Cheng Diao, Kwon Ho Hong, Jin-Jun Rao, Pei-Liang Zhao
Bioorganic & Medicinal Chemistry Letters.2019; 29(1): 22. CrossRef - Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics
Jason H. Gill, Kimberly L. Rockley, Carol De Santis, Asma K. Mohamed
Pharmacology & Therapeutics.2019; 202: 18. CrossRef - Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment
Na Shen, Jing Wu, Chenguang Yang, Haiyang Yu, Shengcai Yang, Tete Li, Jingtao Chen, Zhaohui Tang, Xuesi Chen
Nano Letters.2019; 19(11): 8021. CrossRef - Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site
Ling Li, Sibo Jiang, Xiaoxun Li, Yao Liu, Jing Su, Jianjun Chen
European Journal of Medicinal Chemistry.2018; 151: 482. CrossRef - Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Ryszard Smolarczyk, Tomasz Cichoń, Ewelina Pilny, Magdalena Jarosz-Biej, Aleksandra Poczkaj, Natalia Kułach, Stanisław Szala
Scientific Reports.2018;[Epub] CrossRef - Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study
In Joon Lee, Myungsu Lee, Soo Jin Kim, You Kyung Kim, Jong Yun Won, Jin Wook Chung
Journal of Vascular and Interventional Radiology.2018; 29(8): 1078. CrossRef - Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516
Su Jung Ham, YoonSeok Choi, Seul-I Lee, Jinil Kim, Young Il Kim, Jin Wook Chung, Kyung Won Kim
Hepatology International.2017; 11(5): 446. CrossRef - Early investigational tubulin inhibitors as novel cancer therapeutics
Kunal Nepali, Ritu Ojha, Hsueh-Yun Lee, Jing-Ping Liou
Expert Opinion on Investigational Drugs.2016; 25(8): 917. CrossRef - Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth
María-Jesús Pérez-Pérez, Eva-María Priego, Oskía Bueno, Maria Solange Martins, María-Dolores Canela, Sandra Liekens
Journal of Medicinal Chemistry.2016; 59(19): 8685. CrossRef - Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis
Souvik Banerjee, Dong-Jin Hwang, Wei Li, Duane Miller
Molecules.2016; 21(11): 1468. CrossRef
- Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics
- 14,558 View
- 143 Download
- 23 Web of Science
- 23 Crossref
- Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort
- Yun-Gyoo Lee, Soo-Mee Bang, Jeong-Ok Lee, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jung Han Song, Tae-Hee Kim, Ki Woong Kim, Jong-Seok Lee
- Cancer Res Treat. 2015;47(2):215-220. Published online August 29, 2014
- DOI: https://doi.org/10.4143/crt.2013.262
-
Abstract
PDFPubReaderePub
- Purpose
We previously reported the prevalence of monoclonal gammopathy of undetermined significance (MGUS) to be 3.3% among an elderly Korean urban cohort recruited during 2005-2006. Here, we report a 5-year follow-up study of the previously identified MGUS cohort.
Materials and Methods
The 680 participants from the initial cohort were followed-up for a median of 5 years. Sera were collected between 2010 and 2011. Two-step screening was performed with standard serum electrophoresis followed by immunofixation and determination of the serum concentration of monoclonal-protein (M-protein).
Results
Of the 680 participants (21 with MGUS), 348 (51%) agreed to participate in the follow-up study and 10 were found to have MGUS. Among the 21 MGUS patients initially identified, nine were followed-up, six had persistent M-protein, and one patient had progressed to multiple myeloma (progression rate, 1.0%/yr). The M-protein disappeared in the remaining two individuals. Among the 339 participants without MGUS who were followed-up, four developed an M-protein. There was no significant difference in survival with respect to the presence of MGUS (p=0.66).
Conclusion
The 5-year follow-up data show that the natural clinical course of MGUS in Korea is similar to that in Western countries. MGUS was not associated with an increased risk of death over the 5-year study period. -
Citations
Citations to this article as recorded by- Prevalence of monoclonal gammopathy of undetermined significance in Shenzhen, China
Anping Xu, Tong Guo, Shuping Zhang, Houlong Luo, Mengxue Shen, Yinghui Ye, Ling Ji
Hematology.2024;[Epub] CrossRef - Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis
Kihyun Kim, Chang-Ki Min, Youngil Koh, Kenichi Ishizawa, Sung-Hyun Kim, Shigeki Ito, Junji Tanaka, Michihiro Uchiyama, Yawara Kawano, Jin Seok Kim, Philippe Moreau, Thomas Martin, Yvonne Dong, Marie-Laure Risse, Kenshi Suzuki
International Journal of Hematology.2022; 116(4): 553. CrossRef - Screening Tests for Early Diagnosis of Multiple Myeloma and Related Plasma Cell Disorders
Jin Seok Kim, Sung-Soo Yoon, Chang-Ki Min, Je-Jung Lee, Dok Hyun Yoon, Kihyun Kim
The Korean Journal of Medicine.2021; 96(5): 371. CrossRef - Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China
Jian-hua Han, Ji-nuo Wang, Yue-lun Zhang, Xin-xin Cao, Dao-bin Zhou, Teng-da Xu, Wei Su, Jian Li
Blood Cancer Journal.2020;[Epub] CrossRef - Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study
Ling Ma, Shuang Xu, Jianhua Qu, Jian Hou, Yang Wang, Lei Wen, Yang Liu, Ying Kang, Ming Jiang, Weijun Fu, Juan Du, Lin Zhou, Xiaojun Huang, Zhaoxia Zhang, Jin Lu
Hematological Oncology.2019; 37(1): 75. CrossRef - The clinical features and prognosis of the monoclonal gammopathy undetermined significance: A single center study
Ling Ma, Shuang Xu, Lei Wen, Yang Liu, Ying Kang, Xiaojun Huang, Jin Lu
Blood Cells, Molecules, and Diseases.2018; 73: 9. CrossRef - Recent advances in multiple myeloma: a Korean perspective
Junshik Hong, Jae Hoon Lee
The Korean Journal of Internal Medicine.2016; 31(5): 820. CrossRef
- Prevalence of monoclonal gammopathy of undetermined significance in Shenzhen, China
- 13,670 View
- 82 Download
- 6 Web of Science
- 7 Crossref
- Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer
- In Sil Choi, Do-Youn Oh, Byoung-Su Kim, Keun-Wook Lee, Jee Hyun Kim, Jong-Seok Lee
- Cancer Res Treat. 2007;39(3):99-103. Published online September 30, 2007
- DOI: https://doi.org/10.4143/crt.2007.39.3.99
-
Abstract
PDFPubReaderePub
Purpose We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer.
Materials and Methods The study patients were chemotherapy-naïve patients (> 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks.
Results A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2~6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4~12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2.
Conclusion This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer.
-
Citations
Citations to this article as recorded by- Fabrication and evaluation of smart pH/thermo dual-responsive injectable intratumoral in situ depot hydrogels for controlled 5-FU delivery
Samiullah Khan, Bangul Khan, Huan Li
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef - Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature
C. de la Fouchardiere, L. Decoster, E. Samalin, C. Terret, C. Kenis, J.P. Droz, C. Coutzac, E. Smyth
Cancer Treatment Reviews.2021; 100: 102289. CrossRef - Fabrication, rheological analysis, and in vitro characterization of in situ chemically cross‐linkable thermogels as controlled and prolonged drug depot for localized and systemic delivery
Samiullah Khan, Naveed Akhtar, Muhammad Usman Minhas
Polymers for Advanced Technologies.2019; 30(3): 755. CrossRef - pH/Thermo-Dual Responsive Tunable In Situ Cross-Linkable Depot Injectable Hydrogels Based on Poly(N-Isopropylacrylamide)/Carboxymethyl Chitosan with Potential of Controlled Localized and Systemic Drug Delivery
Samiullah Khan, Naveed Akhtar, Muhammad Usman Minhas, Syed Faisal Badshah
AAPS PharmSciTech.2019;[Epub] CrossRef - CHEMOTHERAPY IN ELDERLY PATIENTS WITH STOMACH CANCER
O. A. Koroleva, L. M. Kogoniya, M. M. Byakhova, A. G. Titov
Malignant tumours.2018; 8(2): 64. CrossRef - Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer
Wanda Liguigli, Gianluca Tomasello, Laura Toppo, Rossana Poli, Silvia Lazzarelli, Federica Negri, Bruno Perrucci, Alessandra Curti, Matteo Brighenti, Gianvito Donati, Morena Nazzari, Mario Martinotti, Marco Vismarra, Massimo Rovatti, Rodolfo Passalacqua
Tumori Journal.2017; 103(1): 93. CrossRef - Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer
Ji-Won Kim, Keun-Wook Lee, Kyu-Pyo Kim, Ju Hyun Lee, Yong Sang Hong, Jeong-Eun Kim, Sun Young Kim, Sook Ryun Park, Byung-Ho Nam, Sang-Hee Cho, Ik-Joo Chung, Young Suk Park, Ho-Suk Oh, Myung-Ah Lee, Hye Jin Kang, Young Iee Park, Eun-Kee Song, Hye Sook Han,
The Oncologist.2017; 22(3): 293. CrossRef - Facile synthesis of gold nanorods/hydrogels core/shell nanospheres for pH and near-infrared-light induced release of 5-fluorouracil and chemo-photothermal therapy
Hui Jin, Xifeng Liu, Rijun Gui, Zonghua Wang
Colloids and Surfaces B: Biointerfaces.2015; 128: 498. CrossRef - Retracted Article: Facile synthesis of quantum dots/mesoporous silica/quantum dots core/shell/shell hybrid microspheres for ratiometric fluorescence detection of 5-fluorouracil in human serum
Rijun Gui, Ajun Wan, Hui Jin
The Analyst.2013; 138(20): 5956. CrossRef - A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases
Vincenzo Catalano, Renato Bisonni, Francesco Graziano, Paolo Giordani, Paolo Alessandroni, Anna Maria Baldelli, Virginia Casadei, David Rossi, Stefano Luzi Fedeli, Silvia D’Emidio, Lucio Giustini, Giammaria Fiorentini
Gastric Cancer.2013; 16(3): 411. CrossRef - FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer
Cheon Woo Lee, Moo-In Park, Seun Ja Park, Won Moon, Hyung Hun Kim, Hae Won Lee, Ki Hwan Ku, Bu Kyung Kim
Korean Journal of Medicine.2012; 82(1): 37. CrossRef - Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes
In Sil Choi, Hye Seung Lee, Keun-Wook Lee, Haeryoung Kim, Ki Hwan Kim, Yu Jung Kim, Jee Hyun Kim, Woo Ho Kim, Jong Seok Lee
Medical Oncology.2011; 28(4): 991. CrossRef - Biodegradable and thermo-sensitive chitosan-g-poly(N-vinylcaprolactam) nanoparticles as a 5-fluorouracil carrier
N. Sanoj Rejinold, K.P. Chennazhi, S.V. Nair, H. Tamura, R. Jayakumar
Carbohydrate Polymers.2011; 83(2): 776. CrossRef - Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
Han Jo Kim, Jun Young Eun, Young Woo Jeon, Jina Yun, Kyoung Ha Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Research and Treatment.2011; 43(3): 154. CrossRef - Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy
Ki Hwan Kim, Keun-Wook Lee, Sun Kyung Baek, Hye Jung Chang, Yu Jung Kim, Do Joong Park, Jee Hyun Kim, Hyung-Ho Kim, Jong Seok Lee
Gastric Cancer.2011; 14(2): 130. CrossRef - Oxaliplatin and Leucovorin Plus Fluorouracil Versus Irinotecan and Leucovorin Plus Fluorouracil Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Adenocarcinoma
Sun Hyung Kang, Jeong Il Kim, Hee Seok Moon, Seok Hyun Kim, Jae Kyu Sung, Byung Seok Lee, Hyun Yong Jeong
The Korean Journal of Gastroenterology.2010; 55(1): 26. CrossRef - Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer
In Sil Choi, Keun-Wook Lee, Ki Hwan Kim, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee
Medical Oncology.2010; 27(3): 992. CrossRef - Three-Weekly S-1 Monotherapy as First-Line Treatment in Elderly Patients with Recurrent or Metastatic Gastric Cancer
Joo Han Lim, Moon Hee Lee, Hyung Gil Kim, Yong Woon Shin, Hyeon Gyu Yi, Seok Hwan Shin, Yoon Seok Hur, Chul Soo Kim, Hye Jeong Chang
Gut and Liver.2010; 4(4): 503. CrossRef - Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer
Hye Jin Kim, Keun-wook Lee, Yu Jung Kim, Do-youn Oh, Jee Hyun Kim, Seock-ah Im, Jong Seok Lee
Acta Oncologica.2009; 48(3): 385. CrossRef
- Fabrication and evaluation of smart pH/thermo dual-responsive injectable intratumoral in situ depot hydrogels for controlled 5-FU delivery
- 12,092 View
- 82 Download
- 19 Crossref
- A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer
- Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha
- Cancer Res Treat. 2005;37(4):208-211. Published online August 31, 2005
- DOI: https://doi.org/10.4143/crt.2005.37.4.208
-
Abstract
PDFPubReaderePub
Purpose Heptaplatin (SKI-2053 R) is a new platinum analogue, with a better toxicity profile than cisplatin, and has antitumor activity even in cisplatin resistant cell lines. 5-fluoruracil (5-FU) has shown synergy with platinum compounds. This phase II trial was designed to determine the efficacy and toxicities of heptaplatin/ 5-FU (5-fluorouracil) for treating stomach cancer.
Materials and Methods Thirty-two patients with advanced, measurable gastric adenocarcinomas were enrolled in this trial. The treatment consisted of heptaplatin, 400 mg/m2/day (1 hour IV infusion), on day 1 and 5-FU, 800 mg/m2/day (12 hours IV infusion), on days 1 to 5. The cycles were repeated every 3 weeks.
Results Of the 26 evaluable patients, 9 had partial responses and 1a complete response (overall response rate, 38%; 95% confidence interval, 19~57%). The median response duration was 23 weeks (range: 4~60 weeks). The median time to progression was 26 weeks (range: 3~68 weeks). The grades III-IV toxicities were mostly hematological toxicities: leucopenia was observed in 11 patients (35%) and thrombocytopenia 4 (13%). No definite neuropathy was observed. Grade I-II nephropathy was also noted: grade I high BUN/creatinine levels occurred in 5 patients (16%), grade II proteinuria 2 (6%), grade I proteinuria 5 (16%). Neutropenic fever developed in 5 patients (16%) and 1 died of pneumonia in a neutropenic state.
Conclusion This study suggests that the regimen of Heptaplatin/5-FU should be effective and have a favorable toxicity profile for the patients suffering with advanced stomach cancer.
-
Citations
Citations to this article as recorded by- Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
S. Shruthi, K. Bhasker Shenoy
ChemistrySelect.2024;[Epub] CrossRef - Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules.2022; 27(8): 2466. CrossRef - Synthesis of novel heptaplatin derivatives and evaluation of their ability to inhibit proliferation of cancer cell lines
W. Xu, D. C. Wang
Russian Journal of General Chemistry.2016; 86(4): 939. CrossRef - The extract of Paris polyphylla exerts apoptotic induction and synergic antiproliferative effect with anticancer drugs in SMMC-7721 human liver cancer cells
Jing Sun, Bao-rui Liu, Jia Wei, Xiao-ping Qian, Li-xia Yu, Ren-hua Guo, Hua Shen, Tong-shan Wang, Yong-qian Shu
Biomedicine & Preventive Nutrition.2011; 1(3): 186. CrossRef - The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef - Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
H.-C. Kwon, M.S. Roh, S.Y. Oh, S.-H. Kim, M.C. Kim, J.-S. Kim, H.-J. Kim
Annals of Oncology.2007; 18(3): 504. CrossRef
- Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
- 11,126 View
- 62 Download
- 6 Crossref
- A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting
- Gyeong-Won Lee, Jung-Hun Kang, Seok-Hyun Kim, Hea Yong Lee, Ho-Cheol Kim, Won-Sup Lee, Jong-Duk Lee, Young-Sil Hwang, Joung-Soon Jang, Jong-Seok Lee
- Cancer Res Treat. 2004;36(5):287-292. Published online October 31, 2004
- DOI: https://doi.org/10.4143/crt.2004.36.5.287
-
Abstract
PDFPubReaderePub
Purpose We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment.
Materials and Methods Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m2 intravenous infusion on day 1 and intravenous ifosfamide 3 g/m2 with Mesna® uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks.
Results One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range: 2.02~3.20 months), and the median survival was 5.24 months (range: 2.99~7.49 months).
Conclusion Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.
-
Citations
Citations to this article as recorded by- The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim
Cancer Research and Treatment.2005; 37(6): 339. CrossRef
- The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
- 11,544 View
- 53 Download
- 1 Crossref
First
Prev
